Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Ding, Qingjie, Zhang, Zhuming, Liu, Jin-Jun, Jiang, Nan, Zhang, Jing, Ross, Tina M., Chu, Xin-Jie, Bartkovitz, David +9 more·2013·Journal of Medicinal Chemistry

DOI 10.1021/jm400487c

Cited by (617)

Items 201–300 of 617

Rational design, synthesis and molecular modeling studies of novel anti-oncological alkaloids against melanoma
Adel S. Girgis, Siva S. Panda, Aladdin M. Srour, Hanaa Farag, Nasser S. M. Ismail, Mohamed Elgendy, Amal Kamal Abdel‐Aziz, ALAN ROY KATRITZKY · 2015 · Organic & Biomolecular Chemistry
Targeting Focal Adhesion Kinase Using Inhibitors of Protein-Protein Interactions
Antoine Mousson, Émilie Sick, Philippe Carl, Denis Dujardin, Jan De Mey, Philippe Rondé · 2018 · Cancers
Emerging therapeutic targets for patients with advanced prostate cancer
Fred Saad C, Neal D. Shore, Tian Zhang, Shikhar Sharma, Helen K. Cho, Ira Allen Jacobs · 2019 · Cancer Treatment Reviews
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
Antoîne Italiano, Wilson H. Miller, Jean‐Yves Blay, Jourik A. Gietema, Yung‐Jue Bang, Linda Mileshkin, Hal W. Hirte, Brian Higgins, Steven D. Blotner, GWEN L. NICHOLS et al. · 2021 · Investigational New Drugs
The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
Krzysztof Puszyński, Alberto Gandolfi, Alberto d’Onofrio · 2014 · PLoS Computational Biology
ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma
Chiao‐En Wu, Tsin Shue Koay, Arman Esfandiari, Yi-Hsuan Ho, Penny E. Lovat, John Lunec · 2018 · Cancers
A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk Neuroblastoma
Eveline Barbieri, Katleen De Preter, Mario Capasso, Peter A. Johansson, Tsz‐Kwong Man, Zaowen Chen, Paris N. Stowers, Gian Paolo Tonini, Frank Speleman, Jason Matthew Shohet · 2013 · PLoS ONE
The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer
Sarah Alexandrou, Sandra Marie George, Christopher John Ormandy, Elgene Lim, Samantha Richelle Oakes, Catherine Elizabeth Caldon · 2019 · International Journal of Molecular Sciences
Zinc‐Catalyzed Enantioselective [3+2] Cycloaddition of Azomethine Ylides Using Planar Chiral [2.2]Paracyclophane‐Imidazoline N,O‐ligands
Sundaravel Vivek Kumar, Patrick J. Guiry · 2022 · Angewandte Chemie International Edition
Dying to Survive—The p53 Paradox
Andrea Lees, Tamas Sessler, Simon S. McDade · 2021 · Cancers
Tetra-substituted imidazoles as a new class of inhibitors of the p53–MDM2 interaction
Andrea Vaupel, Guido Bold, Alain De Pover, Therese‐Marie Stachyra, Joanna Hergovich Lisztwan, Joerg A. Kallen, Keiichi Masuya, Pascal Furet · 2014 · Bioorganic & Medicinal Chemistry Letters
An MDM2 degrader for treatment of acute leukemias
Bridget Kelly Marcellino, Xiaobao Yang, H. Ümit Kanıskan, Claudia Brady, He Chen, Karie Chen, Xing Qiu, Cara Clementelli, Lauren Herschbein, Zhijun Li et al. · 2022 · Leukemia
Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens
Ali Mohammed Alaseem · 2023 · Saudi Pharmaceutical Journal
Drug Discovery Approaches to Target E3 Ligases
A. Rodríguez-Gimeno, Carles Galdeano · 2024 · ChemBioChem
P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia
Stefania Trino, Luciana De Luca, Ilaria Laurenzana, Antonella Caivano, Luigi Del Vecchio, Giovanni Martinelli, Pellegrino Musto · 2016 · Frontiers in Pharmacology
Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma
Alan Van Goethem, Nurten Yigit, Myrthala Moreno‐Smith, Sanjeev A. Vasudevan, Eveline Barbieri, Frank Speleman, Jason Matthew Shohet, Jo Vandesompele, Tom Van Maerken · 2017 · Oncotarget
MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma
Xiaoqin Fan, Yujie Wang, Jian Song, Hanwei Wu, Ming Yang, Lu Lu, Xin Weng, Lusha Liu, Guohui Nie · 2019 · Cancer Biology & Therapy
Phase-separated condensate-aided enrichment of biomolecular interactions for high-throughput drug screening in test tubes
Min Zhou, Weiping Li, Jian Li, Leiming Xie, Rongbo Wu, Liang Wang, Shuai Fu, WEI WEN SU, Jianyang Hu, Jing Wang et al. · 2020 · Journal of Biological Chemistry
UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma
Emily S. Reardon, Vivek Shukla, Sichuan Xi, Sudheer Kumar Gara, Yi Liu, David M. Straughan, Mary F. Zhang, Julie A. Hong, Eden C. Payabyab, Anju Kumari et al. · 2020 · Journal of Thoracic Oncology
p53 regulated senescence mechanism and role of its modulators in age-related disorders
Girija Pawge, Gopal Lal Khatik · 2021 · Biochemical Pharmacology
A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction
Ewa Surmiak, Aleksandra Twarda‐Clapa, Krzysztof M. Żak, Bogdan Musielak, Marcin D. Tomala, Katarzyna Kubica, P. Grudnik, Mariusz Madej, Mateusz Jabłoński, Jan Potempa et al. · 2016 · ACS Chemical Biology
Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment
Cristina Camps-Fajol, Debora Cavero, Jordi Minguillón, Jordi Surrallés · 2024 · Pharmacological Research
Chemical Variations on the p53 Reactivation Theme
Carlos J. A. Ribeiro, Cecília M. P. Rodrigues, Rui Moreira, Maria M. M. Santos · 2016 · Pharmaceuticals
Identification of new inhibitors of Mdm2–p53 interaction via pharmacophore and structure-based virtual screening
Noor Atatreh, Mohammad A. Ghattas, Sanaa K. Bardaweel, Sara Al Rawashdah, Mohammad Al Sorkhy · 2018 · Drug Design Development and Therapy
Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors
Tatyana A. Grigoreva, Daria Novikova, Alexey Petukhov, Maxim Gureev, Alexander V. Garabadzhiu, Gerry Melino, Nickolai A. Barlev, Vyacheslav G. Tribulovich · 2017 · Bioorganic & Medicinal Chemistry Letters
Protein–protein interactions in bacteria: a promising and challenging avenue towards the discovery of new antibiotics
Laura Carro · 2018 · Beilstein Journal of Organic Chemistry
BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models
Hao, Xiaoguang, Bahia, Ravinder K, Cseh, Orsolya, Bozek, Danielle A, Blake, Sophia, Rinnenthal, Jörg, Weyer-Czernilofsky, Ulrike, Rudolph, Dorothea, Artee Luchman, H · 2023 · Neuro-Oncology
IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma
Chengtao Sun, Mengzhen Li, Lian Zhang, Feifei Sun, Huimou Chen, Yanjie Xu, Yingxia Lan, Li Zhang, Suying Lü, Jia Zhu et al. · 2022 · Cell Death and Disease
FBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex
Benita Sjögren, Steven M. Swaney, Richard R. Neubig · 2015 · PLoS ONE
An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53
Yongmi Huang, Zhihao Jiao, Yuqing Fu, Yue Hou, Jinxiao Sun, Feiran Hu, Shangzhe Yu, Kexin Gong, Yiru Liu, Guisen Zhao · 2024 · European Journal of Medicinal Chemistry
Developing structure–activity relationships from an HTS hit for inhibition of the Cks1–Skp2 protein–protein interaction
Rajinder Singh, Arvinder S. Sran, David C. Carroll, Jianing Huang, Lyuben M. Tsvetkov, Xiulan Zhou, Julie Sheung, John McLaughlin, Sarkiz D. Issakani, Donald G. Payan et al. · 2015 · Bioorganic & Medicinal Chemistry Letters
Efficient synthesis of novel antiproliferative steroidal spirooxindoles via the [3+2] cycloaddition reactions of azomethine ylides
Bin Yu, Xiao-Nan Sun, Xiaojing Shi, Ping‐Ping Qi, Yi‐Chao Zheng, De‐Quan Yu, Hong‐Min Liu · 2015 · Steroids
Deregulated transcription factors and poor clinical outcomes in cancer patients
Yiwei Li, Asfar Sohail Azmi, Ramzi M. Mohammad · 2022 · Seminars in Cancer Biology
Mathematical modeling for novel cancer drug discovery and development
Ping Zhang, Vladimir Brusić · 2014 · Expert Opinion on Drug Discovery
Spirooxadiazoline oxindoles with promising in vitro antitumor activities
Carlos J. A. Ribeiro, Joana D. Amaral, Cecília M. P. Rodrigues, Rui Moreira, Maria M. M. Santos · 2015 · MedChemComm
Syringa pinnatifolia Hemsl. fraction protects against myocardial ischemic injury by targeting the p53-mediated apoptosis pathway
Xiao Feng, Ruifei Zhang, Junjun Li, Yuan Cao, Feng Zhao, Xiaolang Du, Xiaoli Gao, Lan Cao, Suyile Chen, Pengfei Tu et al. · 2018 · Phytomedicine
Design and Development of IKZF2 and CK1α Dual Degraders
David K. Miyamoto, Nicole M. Curnutt, Sun‐Mi Park, Alexios Stavropoulos, Michael G. Kharas, Christina M. Woo · 2023 · Journal of Medicinal Chemistry
1,4,5-Trisubstituted Imidazole-Based p53–MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers
Aleksandra Twarda‐Clapa, Sylwia Krzanik, Katarzyna Kubica, Katarzyna Guzik, Beata Łabuzek, Constantinos G. Neochoritis, Kareem Khoury, Kaja Kowalska, Mirosława Czub, Grzegorz Dubin et al. · 2017 · Journal of Medicinal Chemistry
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Hongyi Zhao, Minhang Xin, San‐Qi Zhang · 2023 · Drug Development Research
The role of E3 ubiquitin ligase HECTD3 in cancer and beyond
Qiuyun Jiang, Fubing Li, Zhuo Cheng, Yanjie Kong, Ceshi Chen · 2019 · Cellular and Molecular Life Sciences
Resistance acquisition to MDM2 inhibitors
Cinatl, Jindrich, Speidel, Daniel, Hardcastle, Ian, Michaelis, Martin · 2014 · Biochemical Society Transactions
MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation
Pellot Ortiz, Karolina I., Rechberger, Julian S., Nonnenbroich, Leo F., Daniels, David J., Sarkaria, Jann N. · 2023 · Biomedicines
Altered pathways and targeted therapy in double hit lymphoma
Yuxin Zhuang, Jinxin Che, Meijuan Wu, Yu Lian Guo, Yongjin Xu, Xiaowu Dong, Haiyan Yang · 2022 · Journal of Hematology & Oncology
The Development of p53-Targeted Therapies for Human Cancers
Yier Lu, Meng Yin Wu, Yang Xu, Lili Yu · 2023 · Cancers
Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis
Olga Fedorova, Alexandra A. Daks, Varvara Petrova, Alexey Petukhov, Larissa Lezina, Oleg Y. Shuvalov, Pavel B. Davidovich, Daria V. Kriger, Ekaterina V. Lomert, Dmitri Tentler et al. · 2018 · Cell Cycle
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma
Lindi Chen, Fabio Pastorino, Philip Berry, Jennifer J. Bonner, Calum Kirk, Katrina M. Wood, Huw D. Thomas, Yan Zhao, Antonio Daga, Gareth J. Veal et al. · 2018 · International Journal of Cancer
Expanding the ligand spaces for E3 ligases for the design of protein degraders
Rahman Shah Zaib Saleem, Martin P. Schwalm, Stefan Knapp · 2024 · Bioorganic & Medicinal Chemistry
Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy
Jiang‐Jiang Qin, Wei Wang, Sushanta Sarkar, Sukesh Voruganti, Rajesh Agarwal, Ruiwen Zhang · 2016 · Oncotarget
Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Maryam Zanjirband, Soheila Rahgozar · 2019 · Current Drug Targets
Discovery of MK-4688 : an Efficient Inhibitor of the HDM2–p53 Protein–Protein Interaction
Michael H. Reutershan, Michelle R. Machacek, Michael D. Altman, Stephane L. Bogen, Mingmei Cai, Carolyn Cammarano, Dapeng Chen, Matthew Christopher, John G. Cryan, Pierre Daublain et al. · 2021 · Journal of Medicinal Chemistry
Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells
Shiyan Zhang, Ziqin Yan, Yafang Li, Yang Gong, Xilin Lyu, Jianfeng Lou, Daizhou Zhang, Xiangjing Meng, Yujun Zhao · 2022 · Journal of Medicinal Chemistry
Protein-protein interaction inhibitors: advances in anticancer drug design
Leonardo L. G. Ferreira, Glaucius Oliva, Adriano Defini Andricopulo · 2016 · Expert Opinion on Drug Discovery
Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA
Jiang‐Jiang Qin, Wei Wang, Sukesh Voruganti, Hui Wang, Weidong Zhang, Ruiwen Zhang · 2015 · Oncotarget
Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21WAF1/CIP1 and p27KIP1 in Cancer Cells
Umamaheswari Natarajan, Thiagarajan Venkatesan, Vijayaraghavan Radhakrishnan, Shila Samuel, Periannan Rasappan, Appu Rathinavelu · 2019 · Medicina
Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition
Ya‐Huei Kuo, Jing Qi, Guerry Cook · 2016 · Experimental Hematology
Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells
Carmela Ciardullo, Erhan Aptullahoğlu, Laura C. Woodhouse, Wei‐Yu Lin, Jonathan Peter Wallis, Helen J. Marr, Scott R Marshall, Nick P. Bown, Elaine Willmore, John Lunec · 2019 · Haematologica
Recent Synthetic Approaches towards Small Molecule Reactivators of p53
Jerson Lima Silva, Carolina G. S. Lima, Luciana Pereira Rangel, Giulia D. S. Ferretti, Fernanda P. Pauli, Ruan C. B. Ribeiro, Thais B. Silva, Fernando de Carvalho da Silva, Vı́tor F. Ferreira · 2020 · Biomolecules
Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma
Phelps, Doris, Bondra, Kathryn, Seum, Star, Chronowski, Christopher, Leasure, Justin, Kurmasheva, Raushan T., Middleton, Steven, Wang, Dian, Mo, Xiaokui, Houghton, Peter J. · 2015 · Pediatric Blood & Cancer
Modern approaches to glioblastoma therapy
Natalya S. Kuznetsova, Софья Валерьевна Гурова, А. С. Гончарова, Е. В. Заикина, Marina Aleksandrovna Gusareva, Зинькович Михаил Сергеевич · 2023 · South Russian Journal of Cancer
Therapeutic Strategies to Activate p53
Angelo Aguilar, Shaomeng Wang · 2022 · Pharmaceuticals
Destruction and Construction: Application of Dearomatization Strategy in Aromatic Carbon–Nitrogen Bond Functionalization
Shuo‐En Wang, Linfei Wang, Qiuqin He, Renhua Fan · 2015 · Angewandte Chemie International Edition
Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2–p53 Interaction
Ming Yu, Yingcai Wang, Jiang Zhu, Michael D. Bartberger, Jude R. Canon, Ada Chen, David T. Chow, John E. Eksterowicz, Brian M. Fox, Jiasheng Fu et al. · 2014 · ACS Medicinal Chemistry Letters
MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)
Rafał Rusiecki, Jakub Witkowski, Joanna A. Jaszczewska‐Adamczak · 2019 · Recent Patents on Anti-Cancer Drug Discovery
Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review
Ruchi Saxena, Craig M. Welsh, You-Wen He · 2024 · Frontiers in Cell and Developmental Biology
Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases
Nicole Blaquière, Elisia Villemure, Steven T. Staben · 2020 · Journal of Medicinal Chemistry
Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma
Jun Lu, David Wood, Evan Ingley, Sulev Kõks, Daniel Wong · 2021 · Molecular Biology Reports
Green tea-derived theabrownin induces cellular senescence and apoptosis of hepatocellular carcinoma through p53 signaling activation and bypassed JNK signaling suppression
Jiaan Xu, Xiujuan Xiao, Bo Yan, Qiang Yuan, Xiao‐Qiao Dong, Quan Du, Jin Zhang, Letian Shan, Zhishan Ding, Li Zhou et al. · 2022 · Cancer Cell International
p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
Myrthala Moreno‐Smith, Anna Lakoma, Zaowen Chen, Ling Tao, Kathleen A. Scorsone, Linda G. Schild, Kevin Aviles-Padilla, Rana Nikzad, Yankai Zhang, Rikhia Chakraborty et al. · 2017 · Clinical Cancer Research
Discovery of novel polycyclic spiro-fused carbocyclicoxindole-based anticancer agents
Lidan Zhang, Wen Ting Ren, Xiaoyan Wang, Jiaying Zhang, Jie Liu, Lifeng Zhao, Xia Zhang · 2016 · European Journal of Medicinal Chemistry
2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation
Daniil R. Bazanov, Nikolay V. Pervushin, Viktoriia Yu. Savitskaya, Л. В. Аникина, Marina V. Proskurnina, Natalia A. Lozinskaya, Gelina S. Kopeina · 2019 · Bioorganic & Medicinal Chemistry Letters
Targeting p53 in chronic lymphocytic leukemia
Riccardo Moia, Paola Boggione, Abdurraouf Mokhtar Mahmoud, Ahad Ahmed Kodipad, Ramesh Adhinaveni, Sruthi Sagiraju, Andrea Patriarca, Gianluca Gaïdano · 2020 · Expert Opinion on Therapeutic Targets
Catalytic asymmetric synthesis of enantioenriched α-deuterated pyrrolidine derivatives
Xin Chang, Xiang Cheng, Chun‐Jiang Wang · 2022 · Chemical Science
Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer
Yan Li, Guangyu Li, Chenwei Zuo, Xiaolin Wang, Fang Han, Yi Jia, Hai Shang, Yu Tian · 2024 · European Journal of Medicinal Chemistry
Antitumour activity of the glycoengineered type II anti‐ CD 20 antibody obinutuzumab ( GA 101) in combination with the MDM 2‐selective antagonist idasanutlin ( RG 7388)
Frank Herting, Sylvia Herter, Thomas Friess, Günther Muth, Marina Bacac, Jitka Šulcová, Pablo Umaña, Markus Dangl, Christian Klein · 2016 · European Journal Of Haematology
Anticancer strategies by upregulating p53 through inhibition of its ubiquitination by MDM2
Abiodun Anifowose, Ayodeji A. Agbowuro, Xiaoxiao Yang, Binghe Wang · 2020 · Medicinal Chemistry Research
The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia
Yuanfei Shi, Jing Ye, Ying Yang, Yanchun Zhao, Huafei Shen, Xiujin Ye, Wanzhuo Xie · 2021 · Frontiers in Oncology
Nutlin-3a Efficacy in Sarcoma Predicted by Transcriptomic and Epigenetic Profiling
Kathleen I. Pishas, Susan J. Neuhaus, Mark Clayer, ANDREAS W. SCHREIBER, David Lawrence, Michelle Perugini, Robert John Whitfield, Gelareh Farshid, Jim Manavis, Steve Chryssidis et al. · 2013 · Cancer Research
Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy
Qin Jiang-Jiang, Sushanta Sarkar, Sukesh Voruganti, Agarwal Rajesh, Wei Ting Wang, Ruiwen Zhang · 2016 · Journal of Biomedical Research
p53: An Attractive Therapeutic Target for Cancer
Krupa R. Patel, Hitesh D. Patel · 2019 · Current Medicinal Chemistry
Chemopreventive Agent 3,3′-Diindolylmethane Inhibits MDM2 in Colorectal Cancer Cells
Xiang Gao, Jingwen Liu, Kwang Bog Cho, Samanth R. Kedika, Bin Guo · 2020 · International Journal of Molecular Sciences
MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma
Chengtao Sun, Mengzhen Li, Yanfen Feng, Feifei Sun, Li Zhang, Yanjie Xu, Suying Lü, Jia Zhu, Junting Huang, Juan Wang et al. · 2020 · OncoTargets and Therapy
The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis
Rui Zhang, Panwen Tian, Bojiang Chen, Tao Wang, Weimin Li · 2019 · Postgraduate Medicine
New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy
Fabio Andreozzi, Fulvio Massaro, Sébastian Wittnebel, Chloé Spilleboudt, Philippe Lewalle, Adriano Salaroli · 2022 · International Journal of Molecular Sciences
Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein–Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy
Jing Cheng, Ziqin Yan, Kailong Jiang, Chen Liu, Dehua Xu, Xilin Lyu, Xiaobei Hu, Shiyan Zhang, Yubo Zhou, Jia Li et al. · 2023 · Journal of Medicinal Chemistry
Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action
Surendra Reddy Punganuru, Viswanath Arutla, Wei Zhao, Mehrdad Rajaei, Hemantkumar S. Deokar, Ruiwen Zhang, John K. Buolamwini, Kalkunte S. Srivenugopal, Wei Wang · 2020 · Cells
Structure and function of MDM2 and MDM4 in health and disease
Ivy Yiyi Zhu, Alec Lloyd, William R. Critchley, Queen Saikia, Dhananjay Jade, Aysha Divan, Elton Zeqiraj, Michael A. Harrison, Christopher John Brown, Sreenivasan Ponnambalam · 2025 · Biochemical Journal
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
Lindy Vernooij, Laurel Tabe Bate-Eya, Lindy K. Alles, Jasmine Y. Lee, Bianca Koopmans, Hunter C. Jonus, Nil A. Schubert, Linda G. Schild, Daphne Lelieveld, David A. Egan et al. · 2021 · Molecular Cancer Therapeutics
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
Cheng Xu, Heng Liu, Christopher J. Pirozzi, Lee H. Chen, Paula K. Greer, Bill H. Diplas, Liwei Zhang, Matthew S. Waitkus, Yiping He, Hai Yan · 2021 · Acta Neuropathologica Communications
GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers
Gaia Bianco, Mairene Coto‐Llerena, John Gallon, Venkatesh Kancherla, Stephanie Taha‐Mehlitz, Mattia Marinucci, Martina Konantz, Sumana Srivatsa, Hesam Montazeri, Federica Panebianco et al. · 2022 · Communications Biology
Practical Synthesis of MDM2 Antagonist RG7388. Part 1: A Cu(II)-Catalyzed Asymmetric [3 + 2] Cycloaddition
Lianhe Shu, Chen Gu, Dan Fishlock, Zizhong Li · 2016 · Organic Process Research & Development
Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?
Brian J. Ball, Eytan M. Stein · 2019 · Haematologica
Reactivation of p53 via MDM2 inhibition
Eugene S. Kim, Jason Matthew Shohet · 2015 · Cell Death and Disease
Cu-catalyzed endo-selective asymmetric 1,3-dipolar cycloaddition of azomethine ylides with ethenesulfonyl fluorides: Efficient access to chiral pyrrolidine-3-sulfonyl fluorides
Yinan Li, Xin Chang, Qi Xiong, Xiu‐Qin Dong, Chun‐Jiang Wang · 2021 · Chinese Chemical Letters
Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core
Daniil R. Bazanov, Nikolay V. Pervushin, Egor V. Savin, Michael D. Tsymliakov, Anita I. Maksutova, Viktoriia Yu. Savitskaya, S. E. Sosonyuk, Yulia A. Gracheva, Michael Yu. Seliverstov, Natalia A. Lozinskaya et al. · 2022 · Pharmaceuticals
Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma
Hanley N. Abramson · 2023 · International Journal of Molecular Sciences
E3 ligases and DUBs target ferroptosis: A potential therapeutic strategy for neurodegenerative diseases
Linxia Lu, Cili Jifu, Jun Xia, Jingtao Wang · 2024 · Biomedicine & Pharmacotherapy
Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy
Kang Chen, Xiu Lan Xin, Lipeng Qiu, Wenpan Li, Guannan Guan, Gang Li, Mingxi Qiao, Xiuli Zhao, Haiyang Hu, Dawei Chen · 2019 · Acta Biomaterialia
Indolo‐pyrido‐isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation of p53‐miR34a axis
Dimiter Bogdanov Avtanski, Arumugam Nagalingam, Joseph E. Tomaszewski, Prabhakar A. Risbood, Michael J. Difilippantonio, Neeraj Kumar Saxena, Sanjay V. Malhotra, Dipali Sharma · 2016 · Molecular Oncology
Structure- and Ligand-Based Virtual Screening Identifies New Scaffolds for Inhibitors of the Oncoprotein MDM2
Douglas R. Houston, Li-Hsuan Yen, Simon B. Pettit, Malcolm D. Walkinshaw · 2015 · PLoS ONE
Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
Qian Zhao, Shanshan Xiong, Can Chen, Hong-Ping Zhu, Xin Xie, Cheng Peng, Gu He, Bo Han · 2022 · Frontiers in Oncology